Hostname: page-component-78c5997874-dh8gc Total loading time: 0 Render date: 2024-11-20T04:01:48.687Z Has data issue: false hasContentIssue false
  • English
  • Français

New Anticonvulsant Medication Uses in Bipolar Disorder

Published online by Cambridge University Press:  07 November 2014

Po W. Wang ,
Terence A. Ketter ,
Olga V. Becker  and
Cecylia Nowakowska
Get access Rights & Permissions [Opens in a new window]

Abstract

Therapy of bipolar disorders is a rapidly evolving field. Lithium has efficacy in classic bipolar disorders whereas divalproex sodium and carbamazepine may have broader spectrum efficacy that includes non-classic bipolar disorder. In the last 10 years, a series of anticonvulsants have been approved for marketing in the United States. Gabapentin has indirect γ-aminobuytric acid-ergic actions, is generally well tolerated, and appears to have anxiolytic, analgesic, and hypnotic effects. Lamotrigine has antiglutamatergic actions and is generally well tolerated (aside from rash in 1 in 10, and serious rash in 1 in 1,000 patients). Lamotrigine is indicated for maintance treatment in bipolar disorder. Emerging evidence suggests lamotrigine may have utility in bipolar disorder patients with depression and treatment-refractory rapid cycling, as well as analgesic effects. Topiramate and zonisamide may allow both weight loss, while topiramate may have specific efficacy in bulimia, binge eating disorder, and alcohol dependence. Two small studies found oxcarbazepine had similar efficacy to lithium and haloperidol in acute mania. Phenytoin, an older anticonvulsant, may have adjunctive acute mania efficacy. Levetiracetam, a newer anticonvulsant, may be worth exploring and has minimal drug-drug interactions. None of these newer agents has been shown effective in a large placebo controlled trial for acute mania. Although the clinical profiles of these newer anticonvulsants do not appear to overlap markedly with divalproex and carbamazepine (except perhaps for oxcarbazepine), these novel agents may still offer important new options in relieving a variety of specific target symptoms in patients with bipolar disorder.

Type
Review Articles
Information
CNS Spectrums , Volume 8 , Issue 12: Bipolar Mood Disorder: Recent Developments Across the Spectrum , December 2003 , pp. 930 - 947
Copyright
Copyright © Cambridge University Press 2003

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1.American Psychiatrie Association. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry. 2002;159(suppl 4):1–50.Google Scholar
2.American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder. Am J Psychiatry. 1994;151(suppl 12):1–36.CrossRefGoogle Scholar
3.Motohashi, N, Ikawa, K, Kariya, T. GABAB receptors are up-regu-lated by chronic treatment with lithium or carbamazepine. GABA hypothesis of affective disorders? Eur J Pharmacol. 1989;166:95–99.CrossRefGoogle ScholarPubMed
4.Motohashi, N. GABA receptor alterations after chronic lithium administration. Comparison with carbamazepine and sodium val-proate. Prog Neuropsychpharmacol Biol Psychiatry. 1992;16:571–579.Google Scholar
5.Lampe, H, Bigalke, H. Carbamazepine blocks NMDA-activated currents in cultured spinal cord neurons. Neuroreport. 1990;1:26–28.CrossRefGoogle ScholarPubMed
6.Post, RM. Time course of clinical effects of carbamazepine: implications for mechanisms of action. J Clin Psychiatry. 1988;49(suppl 4):35–48.Google ScholarPubMed
7.Ambrosio, AF, Soares-Da-Silva, P, Carvalho, CM, Carvalho, AP. Mechanisms of action of carbamazepine and its derivatives, oxcarbazepine, BIA 2-093, and BIA 2-024. Neurochem Res. 2002;27:121–130.CrossRefGoogle ScholarPubMed
8.Ketter, TA, Post, RM, Pazzaglia, PJ, Marangell, LB, George, MS, Callahan, AM. Carbamazepine. In: Mania: Clinical and Research Perspectives. Goodnick, P, ed. Washington, DC: American Psychiatric Press; 1998;63–300.Google Scholar
9.Nicol, CF. A four year double-blind study of tegretol in facial pain. Headache. 1969;9:54–57.CrossRefGoogle ScholarPubMed
10.Post, RM, Uhde, TW, Roy-Byrne, PP, Joffe, RT. Antidepressant effects of carbamazepine. Am J Psychiatry. 1986;143:29–34.Google ScholarPubMed
11.Uhde, TW, Stein, MB, Post, RM. Lack of efficacy of carbamazepine in the treatment of panic disorder. Am J Psychiatry. 1988;145:1104–1109.Google ScholarPubMed
12.Weisler, RH, Kalali, AH, Ketter, TA. A multicenter, randomized, double-blind, placebo-controlled trial of extended-release carba-mazepine capsules as monontherapy in patients with manic or mixed bipolar disorder. J Clin Psychiatry. In press.Google Scholar
13.Ketter, TA, Kalali, AH, Weisler, RH. A 6-month, multicenter, open-label evaluation of beaded, extended release carbamazepine capsule monotherapy in bipolar disorder patients with manic or mixed episodes. J Clin Psychiatry. In press.Google Scholar
14.Greil, W, Kleindienst, N, Erazo, N, Muller-Oerlinghausen, B. Differential response to lithium and carbamazepine in the prophylaxis of bipolar disorder. J Clin Psychopharmacol. 1998;18:455–60.CrossRefGoogle ScholarPubMed
15.Ketter, TA, Post, RM, Worthington, K. Principles of clinically important drug interactions with carbamazepine. Part I. J Clin Psychopharmacol. 1991;11:198–203.Google ScholarPubMed
16.Ketter, TA, Post, RM, Worthington, K. Principles of clinically important drug interactions with carbamazepine. Part II. J Clin Psychopharmacol. 1991;11:306–313.Google ScholarPubMed
17.Tohen, M, Castillo, J, Baldessarini, RJ, Zarate, C Jr., Kando, JC. Blood dyserasias with carbamazepine and valproate: a pharma-coepidemiological study of 2,228 patients at risk. Am J Psychiatry. 1995;152:413–418.Google Scholar
18.Mattson, RH, Cramer, JA, Collins, JF. A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. The Department of Veterans Affairs Epilepsy Cooperative Study No. 264 Group. N Engl J Med. 1992;327:765–771.CrossRefGoogle ScholarPubMed
19.Rattya, J, Vainionpaa, L, Knip, M, Lanning, P, Isojarvi, JI. The effects of valproate, carbamazepine, and oxcarbazepine on growth and sexual maturation in girls with epilepsy. Pediatrics. 1999;103:588–593.CrossRefGoogle ScholarPubMed
20.Löscher, W. Valproate: a reappraisal of its pharmacodynamic properties and mechanisms of action. Prog Neurobiol. 1999;58:31–59.CrossRefGoogle ScholarPubMed
21.Pope, HG Jr, McElroy, SL, Keck, PE Jr, Hudson, JI. Valproate in the treatment of acute mania. A placebo-controlled study. Arch Gen Psychiatry. 1991;48:62–68.CrossRefGoogle Scholar
22.Bowden, CL, Brugger, AM, Swann, AC, et al.Efficacy of divalproex vs lithium and placebo in the treatment of mania. The Depakote Mania Study Group. JAMA. 1994;271:918–24.CrossRefGoogle ScholarPubMed
23.Freitag, FG, Collins, SD, Carlson, HA, et al.A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis. Neurology. 2002;58:1652–1659.CrossRefGoogle ScholarPubMed
24.Keck, PE Jr, Taylor, VE, Tugrul, KC, McElroy, SL, Bennett, JA. Valproate treatment of panic disorder and lactate-induced panic attacks. Biol Psychiatry. 1993;33:542–546.CrossRefGoogle ScholarPubMed
25.Winsberg, ME, DeGolia, SG, Strong, CM, Ketter, TA. Divalproex therapy in medication-naive and mood-stabilizer-naive bipolar II depression. J Affect Disord. 2001;67:207–212.CrossRefGoogle ScholarPubMed
26.Bowden, CL, Calabrese, JR, McElroy, SL, et al.A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group. Arch Gen Psychiatry. 2000;57:481–489.CrossRefGoogle ScholarPubMed
27.Hirschfeld, RM, Allen, MH, McEvoy, JP, Keck, PE Jr, Russell, JM. Safety and tolerability of oral loading divalproex sodium in acutely manic bipolar patients. J Clin Psychiatry. 1999;60:815–818.CrossRefGoogle ScholarPubMed
28.Bowden, CL, Janicak, PG, Orsulak, P, et al.Relation of serum valproate concentration to response in mania. Am J Psychiatry. 1996;153:765–770.Google ScholarPubMed
29.Taylor, CP, Gee, NS, Su, TZ, et al.A summary of mechanistic hypotheses of gabapentin pharmacology. Epilepsy Res. 1998;29:233–249.CrossRefGoogle ScholarPubMed
30.Petroff, OA, Rothman, DL, Behar, KL, Lamoureux, D, Mattson, RH. The effect of gabapentin on brain gamma-aminobutyric acid in patients with epilepsy. Ann Neurol. 1996;39:95–99.CrossRefGoogle ScholarPubMed
31.Gee, NS, Brown, JP, Dissanayake, VU, Offord, J, Thurlow, R, Woodruff, GN. The novel anticonvulsant drug, gabapentin (Neurontin), binds to the alpha2delta subunit of a calcium channel. J Biol Chem. 1996;271:5768–5776.CrossRefGoogle Scholar
32.Pande, AC, Davidson, JR, Jefferson, JW, et al.Treatment of social phobia with gabapentin: a placebo-controlled study. J Clin Psychopharmacol. 1999;19:341–348.CrossRefGoogle ScholarPubMed
33.Pande, AC, Pollack, MH, Crockatt, J, et al.Placebo-controlled study of gabapentin treatment of panic disorder. J Clin Psychopharmacol. 2000;20:467–471.CrossRefGoogle ScholarPubMed
34.Wang, PW, Santosa, C, Schumacher, M, Winsberg, ME, Strong, C, Ketter, TA. Gabapentin augmentation therapy in bipolar depression. Bipolar Disord. 2002;4:296–301.CrossRefGoogle ScholarPubMed
35.Backonja, MM. Gabapentin monotherapy for the symptomatic treatment of painful neuropathy: a multicenter, double-blind, placebo-controlled trial in patients with diabetes mellitus. Epilepsia. 1999;40(suppl 6):S57–S59; discussion S73-S74.CrossRefGoogle ScholarPubMed
36.Rowbotham, M, Harden, N, Stacey, B, Bernstein, P, Magnus-Miller, L. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA. 1998;280:1837–1842.CrossRefGoogle ScholarPubMed
37.Pande, AC, Crockatt, J, Janney, CA, et al.Gabapentin in bipolar disorder: a placebo-controlled trial of adjunctive therapy. Bipolar Disord. 2000;2:249–255.CrossRefGoogle ScholarPubMed
38.Frye, MA, Ketter, TA, Kimbrell, TA, et al.A placebo controlled evaluation of lamotrigine and gabapentin monotherapy in mood disorders. J Clin Psychopharmacology. 2000;20:607–614.CrossRefGoogle ScholarPubMed
39.Frye, MA, Kimbrell, TA, Dunn, RT, et al.Gabapentin does not alter single-dose lithium pharmacokinetics. J Clin Psychopharmacol. 1998;18:461–464.CrossRefGoogle Scholar
40.Xie, X, Hagan, RM. Cellular and molecular actions of lamotrigine: Possible mechanisms of efficacy in bipolar disorder. Neuro psychobiology. 1998;38:119–130.Google ScholarPubMed
41.Marson, AG, Kadir, ZA, Hutton, JL, Chadwick, DW. The new antiepileptic drugs: a systematic review of their efficacy and tolerability. Epilepsia. 1997;38:859–880.CrossRefGoogle ScholarPubMed
42.Eisenberg, E, Lurie, Y, Braker, C, Daoud, D, Ishay, A. Lamotrigine reduces painful diabetic neuropathy: a randomized, controlled study. Neurology. 2001;57:505–509.CrossRefGoogle ScholarPubMed
43.Calabrese, JR, Bowden, CL, Sachs, GS, Ascher, JA, Monaghan, E, Rudd, GD. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. J Clin Psychiatry. 1999;60:79–88.CrossRefGoogle ScholarPubMed
44.Bowden, CL, Calabrese, JR, Sachs, G, et al.A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry. 2003;60:392–400.CrossRefGoogle ScholarPubMed
45.Calabrese, JR, Suppes, T, Bowden, CL, et al.A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. Lamictal 614 Study Group. J Clin Psychiatry. 2000;61:841–850.CrossRefGoogle ScholarPubMed
46.Bowden, C, Calabrese, J, Ascher, J, et al. Spectrum of efficacy of lamotrigine in bipolar disorder: overview of double-blind placebo-controlled studies. Paper presented at: Annual Meeting of the American College of Neuropsychopharmacology; December 1014, 2000; San Juan, PR.Google Scholar
47.Messenheimer, JA, Tennis, P. Stevens-Johnson syndrome and toxic epidermal necrolysis with antiepileptic drugs commonly used in Germany: adult and pediatric incidence estimates from registry and prescription data [abstract]. Neurology. 2002;58(suppl 3):A175–A176.Google Scholar
48.Calabrese, JR, Sullivan, JR, Bowden, CL, et al.Rash in multicenter trials of lamotrigine in mood disorders: clinical relevance and management. Clin Psychiatry. 2002;63:1012–1019.CrossRefGoogle ScholarPubMed
49.Chandler, RA, O'Keeffe, CM, Wang, PW, et alLow incidence of lamotrigine treatment-emergent rash with dermatology precautions. Paper presented at: Annual Meeting of the American Psychiatric Association; 05 17-22, 2003; San Francisco, Calif.Google Scholar
50.Masia, SL, Ettinger, E, Devinsky, O. Incidence of rash after rapid reintroduction of lamotrigine. Paper presented at: Annual Meeting of the American Academy of Neurology; 03 29-April 5, 2003; Honolulu, Hawaii.Google Scholar
51.Warner, T, Patsalos, PN, Prevett, M, Elyas, AA, Duncan, JS. Lamotrigine-induced carbamazepine toxicity: an interaction with carbamazepine-10,11-epoxide. Epilepsy Res. 1992;11:147–150.CrossRefGoogle ScholarPubMed
52.Malminiemi, K, Keranen, T, Kerttula, T, Moilanen, E, Ylitalo, P. Effects of short-term lamotrigine treatment on pharmacokinetics of carbamazepine. Int J Clin Pharmacol Ther. 2000;38:540–545.CrossRefGoogle ScholarPubMed
53.Anderson, GD, Yau, MK, Gidal, BE, et al.Bidirectional interaction of valproate and lamotrigine in healthy subjects. Clin Pharmacol Ther. 1996;60:145–156.CrossRefGoogle ScholarPubMed
54.Kaufman, KR, Gerner, R. Lamotrigine toxicity secondary to sertraline. Seizure. 1998;7:163–165.CrossRefGoogle ScholarPubMed
55.Ketter, TA, Calabrese, JR. Stabilization of mood from below versus above baseline in bipolar disorder: a new nomenclature. J Clin Psychiatry. 2002;63:146–151.CrossRefGoogle ScholarPubMed
56.Shank, RP, Gardocki, JF, Streeter, AJ, Maryanoff, BE. An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action. Epilepsia. 2000;41(suppl 1):S3–S9.CrossRefGoogle ScholarPubMed
57.White, HS, Brown, SD, Woodhead, JH, Skeen, GA, Wolf, HH. Topiramate enhances GABA-mediated chloride flux and GABA-evoked chloride currents in murine brain neurons and increases seizure threshold. Epilepsy Res. 1997;28:167–179.CrossRefGoogle ScholarPubMed
58.Petroff, OA, Hyder, F, Mattson, RH, Rothman, DL. Topiramate incteases brain GABA, homocarnosine, and pyrrolidinone in patients with epilepsy. Neurology. 1999;52:473–478.CrossRefGoogle ScholarPubMed
59.Kanda, T, Kurokawa, M, Tamura, S, et al.Topiramate reduces abnormally high extracellular levels of glutamate and aspartate in the hippocampus of spontaneously epileptic tats (SER). Life Sci. 1996;59:1607–1616.CrossRefGoogle Scholar
60.Storey, JR, Calder, CS, Hart, DE, Potter, DL. Topiramate in migraine prevention: a double-blind, placebo-controlled study. Headache. 2001;41:968–975.CrossRefGoogle ScholarPubMed
61.Johnson, BA, Ait-Daoud, N, Bowden, CL, et al.Oral topitamate for treatment of alcohol dependence: a randomised controlled trial. Lancet. 2003;361:1677–1685.CrossRefGoogle Scholar
62.Calabrese, JR, Keck, PE Jr, McElroy, SL, Shelton, MD. A pilot study of topiramate as monotherapy in the treatment of acute mania. J Clin Psychopharmacol. 2001;21:340–342.CrossRefGoogle ScholarPubMed
63.Schlatter, FJ, Soutullo, CA, Cervera-Enguix, S. First break of mania associated with topiramate treatment. J Clin Psychopharmacol. 2001;21:464–466.CrossRefGoogle ScholarPubMed
64.Jochum, T, Bar, KJ, Sauer, H. Topiramate induced manic episode. J Neurol Neurosurg Psychiatry. 2002;73:208–209.CrossRefGoogle ScholarPubMed
65.McIntyre, RS, Mancini, DA, McCann, S, Srinivasan, J, Sagman, D, Kennedy, SH. Topiramate versus bupropion SR when added to mood stabilizer therapy for the depressive phase of bipolar disorder: a preliminary single-blind study. Bipolar Disord. 2002;4:207–213.CrossRefGoogle ScholarPubMed
66.Ben-Menachem, E, Henriksen, O, Dam, M, et al.Double-blind, placebo-controlled trial of topiramate as add-on therapy in patients with refractory partial seizures. Epilepsia. 1996;37:539–543.CrossRefGoogle ScholarPubMed
67.Reimherr, FW, Hoopes, SP, Karvois, D, Karim, R, Kamin, M, Rosenthal, NE. Topiramate in the treatment of bulimia nervosa: additional efficacy. Paper presented at: Annual Meeting of the American Psychiatric Association; 05 18-23, 2002; Philadelphia, Penn.Google Scholar
68.McElroy, SL, Arnold, LM, Shapira, NA, et al.Topiramate in the treatment of binge eating disorder associated with obesity: a randomized, placebo-controlled trial. Am J Psychiatry. 2003;160:255–261.CrossRefGoogle ScholarPubMed
69.Ketter, TA, Wang, PW, Tate, DL, Rennicke, CM, Hier, AM, Strong, CM. Low dose adjunctive topitamate attenuates weight gain in bipolar disorder patients. Paper presented at: 22nd Congress of Collegium Internationale Neuro-Psychopharmacologicum; 07 9-13, 2000; Brussels, Belgium.Google Scholar
70.Rosenfeld, WE. Topiramate: a review of preclinical, pharmacoki-netic, and clinical data. Clin Ther. 1997;19:1294–308.CrossRefGoogle ScholarPubMed
71.Ghaemi, SN, Manwani, SG, Katzow, JJ, Ko, JY, Goodwin, FK. Topiramate treatment of bipolat spectrum disorders: a retrospective chart review. Ann Clin Psychiatry. 2001;13:185–189.CrossRefGoogle ScholarPubMed
72.Rhee, DJ, Goldberg, MJ, Parrish, RK. Bilateral angle-closure glaucoma and ciliary body swelling from topiramate. Arch Ophthalmol. 2001;119:1721–1723.Google ScholarPubMed
73.Rosenfeld, WE, Doose, DR, Walker, SA, Nayak, RK. Effect of topiramate on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in patients with epilepsy. Epilepsia. 1997;38:317–323.CrossRefGoogle ScholarPubMed
74.Meldrum, BS, Chapman, AG. Basic mechanisms of gabitril (tiagabine) and future potential developments. Epilepsia. 1999; 40 Suppl 9:S2–6.CrossRefGoogle ScholarPubMed
75.Kaufman, KR. Adjunctive tiagabine treatment of psychiatric disorders: three cases. Ann Clin Psychiatry. 1998;10:181–184.CrossRefGoogle ScholarPubMed
76.Schaffer, L, Schaffer, C, Howe, J. An open case series on the utility of tiagabine as an augmentation in refractory bipolar outpatients. J Affect Disord. 2002;71:259.CrossRefGoogle ScholarPubMed
77.Grunze, H, Erfurth, A, Marcuse, A, Amann, B, Normann, C, Walden, J. Tiagabine appears not to be efficacious in the treatment of acute mania. J Clin Psychiatry. 1999;60:759–762.CrossRefGoogle Scholar
78.Schapel, G, Chadwick, D. Tiagabine and non-convulsive status epilepticus. Seizure. 1996;5:153–156.CrossRefGoogle ScholarPubMed
79.Emrich, HM. Studies with (Trileptal) oxcarbazepine in acute mania. Int Clin Psychopharmacology. 1990;5(suppl 1):83–88.Google Scholar
80.Friis, ML, Kristensen, O, Boas, J, et al.Therapeutic experiences with 947 epileptic out-patients in oxcarbazepine treatment. Acta Neurol Scand. 1993;87:224–227.CrossRefGoogle ScholarPubMed
81.Smith, PE. Clinical recommendations for oxcarbazepine. Seizure. 2001;10:87–91.CrossRefGoogle ScholarPubMed
82.Physicians' Desk Reference. 57th ed. Montvale, NJ: Thomson PDR; 2003.Google Scholar
83.Kaufman, KR, Gerner, R. Adjunctive oxcatbazepine in affective disorder with hyponatremic seizure: case analysis [abstract]. Epilepsia. 2002;43(supp 18): 149–150.Google Scholar
84.Baruzzi, A, Albani, F, Riva, R. Oxcarbazepine: pharmacokinetic interactions and their clinical relevance. Epilepsia. 1994;35:S14–S19.CrossRefGoogle ScholarPubMed
85.Keranen, T, Jolkkonen, J, Jensen, PK, Menge, GP, Andersson, P. Absence of interaction between oxcarbazepine and erythromycin. Acta Neurol Scand. 1992;86:120–123.CrossRefGoogle ScholarPubMed
86.Fattore, C, Cipolla, G, Gatti, G, et al.Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbazepine in healthy women. Epilepsia. 1999;40:783–787.CrossRefGoogle ScholarPubMed
87.Oommen, KJ, Mathews, S. Zonisamide: a new antiepileptic drug. Clin Neuropharmacol. 1999;22:192–200.Google ScholarPubMed
88.Mimaki, T, Suzuki, Y, Tagawa, T, Karasawa, T, Yabuuchi, H. Interaction of zonisamide with benzodiazepine and GABA receptors in rat brain. Med J Osaka Univ., 1990;39:13–17.Google ScholarPubMed
89.Okada, M, Kawata, Y, Mizuno, K, Wada, K, Kondo, T, Kaneko, S. Interaction between Ca2+, K+, carbamazepine and zonisamide on hippocampal extracellular glutamate monitoted with a microdialysis electrode. Br J Pharmacol. 1998;124:1277–1285.CrossRefGoogle ScholarPubMed
90.Chadwick, DW, Marson, AG. Zonisamide add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev. 2002(2):CD001416.Google ScholarPubMed
91.Morris, G. The effect of zonisamide administration on patient weight. Paper presented at: 4th European Congress on Epileptology; 7-12 10, 2000; Florence, Italy.Google Scholar
92.Gadde, KM, Franciscy, DM, Wagner, R. Zonisamide in obesity: a 16-week randomized trial. Paper presented at: annual meeting of the American Psychiatric Association; Philadelphia, Penn; 05 18-23, 2002.Google Scholar
93.Kanba, S, Yagi, G, Kamijima, K, et al.The first open study of zon-isamide, a novel anticonvulsant, shows efficacy in mania. Prog Neuropsychopharmacol Biol Psychiatry. 1994;18:707–715.Google ScholarPubMed
94.Gadde, KM, Franciscy, DM, Wagner, HR 2nd, Krishnan, KR. Zonisamide for weight loss in obese adults: a randomized controlled trial. JAMA. 2003;289:1820–1825.CrossRefGoogle ScholarPubMed
95.Yang, Y, Nowakowska, C, Becker, O, Schumacher, M, Strong, CM, Wang, P, Ketter, TA. Weight loss during first two months of open adjunctive zonisamide for obesity in bipolat disorder patients. Paper presented at: Annual Meeting of the American Psychiatric Association; 05 17-22, 2003; San Francisco, Calif.Google Scholar
96.Loscher, W, Honack, D, Bloms-Funke, P. The novel antiepileptic drug levetiracetam (ucb L059) induces alterations in GABA metabolism and turnover in discrete areas of rat brain and reduces neuronal activity in substantia nigra pars reticulata. Brain Res. 1996;735:208–216.CrossRefGoogle ScholarPubMed
97.Grant, R, Shorvon, SD. Efficacy and tolerability of 1000-4000 mg per day of levetitacetam as add-on thetapy in patients with refractory epilepsy. Epilepsy Res. 2000;42:89–95.CrossRefGoogle Scholar
98.Goldberg, JF, Burdick, KE. Levetiracetam for acute mania. Am J Psychiatry. 2002;159:148.CrossRefGoogle ScholarPubMed
99.Yaari, Y, Selzer, ME, Pincus, JH. Phenytoin: mechanisms of its anti-convulsant action. Ann Neurol. 1986;20:171–184.CrossRefGoogle Scholar
100.Mishory, A, Yaroslavsky, Y, Bersudsky, Y, Belmaker, RH. Phenytoin as an antimanic anticonvulsant: a controlled study. Am J Psychiatry. 2000;157:463–465.CrossRefGoogle ScholarPubMed
101.Applebaum, J, Levine, J, Belmaker, RH. Intravenous fosphenytoin in acute mania. J Clin Psychiatry. 2003;64:408–409.CrossRefGoogle ScholarPubMed